52665-48-2

Basic information

• Product Name: FURAN-2-SULFONYL CHLORIDE
• Synonyms: FURAN-2-SULFONYL CHLORIDE;FURAN-2-SULPHONYL CHLORIDE;Furane-2-sulfonylchloride;Furan-2-sulphonyl chloride 97+%;2-(Chlorosulphonyl)furan
• CAS NO: 52665-48-2
• Molecular Formula: C₄H₃ClO₃S
• Molecular Weight: 166.58
• Product Categories: Furans, Benzofurans & Dihydrobenzofurans;Sulphonyl Chlorides
• Mol File: 52665-48-2.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 79 °C
• Flash Point: 90.6 °C
• Appearance: /
• Density: 1.529 g/cm³
• Vapor Pressure: 0.125mmHg at 25°C
• Refractive Index: 1.515
• CAS DataBase Reference: FURAN-2-SULFONYL CHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: FURAN-2-SULFONYL CHLORIDE(52665-48-2)
• EPA Substance Registry System: FURAN-2-SULFONYL CHLORIDE(52665-48-2)

Safety Data

• Hazard Codes: C,Xi
• Statements: 36
• Safety Statements: 26
• Hazardous Substances Data: 52665-48-2(Hazardous Substances Data)

Usage

General Description

Furan-2-sulfonyl chloride, also known as 2-furoyl chloride, is a chemical compound with the molecular formula C5H3ClO2S. It is a colorless to pale yellow liquid that is used as a versatile building block in organic synthesis. Furan-2-sulfonyl chloride is commonly used as a reagent in the production of pharmaceuticals, agrochemicals, and dyes. It is also employed in the synthesis of various functionalized furans, which are important intermediates in the production of fine chemicals and materials. Additionally, furan-2-sulfonyl chloride is utilized in the modification of biologically active compounds to improve their pharmacological properties. However, it is important to handle this compound with caution as it is corrosive and may cause irritation to the skin, eyes, and respiratory system.

InChI:InChI=1/C4H3ClO3S/c5-9(6,7)4-2-1-3-8-4/h1-3H

Upstream product

• 110-00-9 furan 
• 64902-60-9 lithium furan-2-sulfinate 

Downstream Products

• 55673-71-7 furan-2-sulfonamide 
• 111711-65-0 5-Ethoxy-1-(furan-2-sulfonyl)-pyrrolidin-2-one 
• 82971-11-7 2-furansulfonic acid 
• 909897-01-4 methyl 4-{[2-[(2-furylsulfonyl)amino]-5-(trifluoromethyl)phenoxy]methyl}benzoate 
• 1195768-77-4 N-{5-[5-(2-chloro-4-pyrimidinyl)-2-(1-methylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2-furansulfonamide 
• 1269421-46-6 methyl 2,6-difluoro-3-(N-(furan-2-ylsulfonyl)(furan-2-sulfonamido))benzoate 
• 1269500-22-2 C₁₉H₂₅N₃O₆S 
• 1186608-20-7 2,6-difluoro-3-(furan-2-sulfonamido)-N-(3-methoxy-1H-pyrazolo[3,4-b]pyridin-5-yl)benzamide 
• 1313217-30-9 tert-butyl [tert-butoxycarbonyl(6-{(furan-2-ylsulfonyl)[4-(1,1-dimethylpentyl)-benzyl]aminomethyl}pyridin-2-yl)amino]acetate 
• 1415030-96-4 C₁₆H₁₆N₄O₅S 
• 1380228-92-1 N-(2,4-difluoro-3-(3-(9-(tetrahydro-2H-pyran-2-yl)-9H-purin-6-yl)pyridin-2-ylamino)phenyl)furan-2-sulfonamide 
• 52260-00-1 2-thiophene sulfonyl hydrazine 

Relevant articles and documents

Development of novel NLRP3-XOD dual inhibitors for the treatment of gout

Gout is a crystalline-related arthropathy caused by the deposition of monosodium urate (MSU). Acute gouty arthritis is the most common first symptom of gout. Studies have shown that NOD-like receptor protein 3 (NLRP3) inflammasome as pattern recognition r

SULFONAMIDE DERIVATIVE AND MEDICINAL USE THEREOF

Provided are sulfonamide derivatives of a specific chemical structure in which a sulfonamide group having, as a substituent, a phenyl group or a heterocyclic group having a hetero atom(s) as a constituent element(s) is present at its terminal, and pharmaceutically acceptable salts thereof. These compounds are novel compounds having excellent α4 integrin-inhibitory action.

N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin

Thienyl-, furyl- and pyrrolyl-sulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, N-(isoxazolyl)thienylsulfonamides, N-(isoxazolyl)furylsulfonamides and N-(isoxazolyl)pyrrolylsulfonamides and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.